Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

>Drug Interactions:

  • Renal clearance of lithium is reduced by diuretics, such as chlorthalidone, increasing the risk of lithium toxicity.
  • Monitor renal function periodically in patients receiving EDARBI or EDARBYCLOR and NSAIDs who are also elderly, volume-depleted (including those on diuretics), or who have compromised renal function, as deterioration of renal function, including possible acute renal failure, may result. These effects are usually reversible. NSAIDs may interfere with antihypertensive effect.
  • Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Please click here for complete EDARBI Prescribing Information or here for complete EDARBYCLOR Prescribing Information.

Indications and Usage
EDARBI and EDARBYCLOR are indicated for the treatment of hypertension to lower blood pressure. EDARBI is an angiotensin II receptor blocker (ARB) and EDARBYCLOR is an ARB and a thiazide-like diuretic combination. EDARBYCLOR may be used if a patient is not adequately controlled on monotherapy or as initial therapy if multiple drugs are needed to help achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. There are no controlled trials demonstrating risk reduction with EDARBI or EDARBYCLOR, but trials with chlorthalidone and at least one pharmacologically similar drug to azilsartan medoxomil have demonst
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a ... its first patient in its study for ischemic ... American Stroke Association, ischemic strokes account for 87 ... enroll qualified patients in the study, entitled "Internal ... of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that on December 24, 2014 ... The Company raised approximately $2.3 million ... to use the net proceeds from the offering ...
(Date:12/24/2014)... and LONDON , December ... orthopedic industry are expected to grow at an average ... terms of value and volume. Hip, knee and spine ... world while in emerging economies they have a lower ... are challenging the use of composites. Non-metallic orthopedic devices ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Nov. 3, 2011 Dyadic International, Inc. ("Dyadic") ... on the discovery, development, manufacture and sale of ... enzyme and biopharmaceutical industries, today announced financial results ... (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO) The financial information ...
... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... the peer-reviewed journal of The Obesity Society. The EQUIP study ... 1,267 severely obese (BMI >/= 35 kg/m 2 ) patients across ... of 14.4% of initial body weight among those who completed the ...
Cached Medicine Technology:Dyadic International Reports 2011 Third Quarter Financial Results 2Dyadic International Reports 2011 Third Quarter Financial Results 3Dyadic International Reports 2011 Third Quarter Financial Results 4Dyadic International Reports 2011 Third Quarter Financial Results 5Dyadic International Reports 2011 Third Quarter Financial Results 6Dyadic International Reports 2011 Third Quarter Financial Results 7Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... complex chronic illnesses can receive effective, less expensive care from ... access to a team of dedicated health care professionals, a ... seriously ill and need either hospitalization or a trip to ... medical home clinic at the University of Texas in Houston ...
(Date:12/25/2014)... is common during the holidays, but there are strategies that ... "Don,t arrive at a party hungry. It may seem logical ... a party, but deprivation leads to hunger, and hunger leads ... in Mount Kisco, N.Y., said in a hospital news release. ... even to have a snack before attending a party when ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... "fountain of youth" drug that can delay the effects of ... study suggests. Seniors received a significant boost to their ... signaling pathway linked to aging and immune function, researchers with ... medication, a version of the drug rapamycin, improved the seniors, ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... U.S. has enough capacity for typical season; experts less sure ... The current swine flu outbreak is raising critical questions about ... the logistics of getting it to the people who need ... cut into this fall,s production of seasonal influenza vaccine, experts ...
... 2nd Annual Disability Leadership & Policy Summit: ... to promote an exchange of ideas between people with disabilities ... health and human service professionals will convene on Wednesday, June ... speakers and their topics include: , , ...
... own, while most Americans agree both are equally ... has contributed to poorer overall family health and ... to healthcare. Two-thirds of Americans (66 percent) believe ... care of their health and their children,s health. ...
... Costs by Reducing UtilizationCOLUMBUS, Ohio, May 18 As ... healthcare costs, Quantum Health, Inc. announced that its Coordinated ... employee, or 14%, in 2008. Over the past ten ... to 4%-5% with no reduction in benefits or cost-shifting ...
... to improve navigation, functionality and user-friendliness. The new website still ... with better design and navigation, users can now access information, ... ... Neptune Beach, FL (PRWEB) May 18, 2009 ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:United Spinal Association's 2nd Annual Disability Leadership & Policy Summit: Health Issues and People with Disabilities 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 2Health News:New Research Finds Recession Has Greater Impact on Health of Parents Than Children 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 2Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 3Health News:Coordinated Health/Care(TM) Saves Participating Employers $1000+ per Employee in 2008 4Health News:International Student Insurance Announces Website Redesign 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5
... Dot Stereo Depth Perception for Both,Gross ... arc) and Fine Depth,Perception. , ,The ... to 40 sec of arc), An ... 100 sec of arc), 1 Pair ...
... Pulsair EasyEye is the only handheld non-contact ... Pulsair EasyEye is streamlined, quiet and now, ... discomfort, just a gentle puff of air. You ... a demonstration on the patient's hand before you ...
The Emit 2000 Phenytoin Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of phenytoin in human serum or plasma. Emit 2000 assays are designed for use with most ...
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
Medicine Products: